BIO-TECHNE Corp (TECH) · Sep 14, 2026 · Other events

Bio-Techne amends Merck merger proxy as shareholder litigation targets vote

Proxy supplemented — one lawsuit, multiple demand letters; vote remains scheduled for September 23

Bio-Techne adds deal-process and valuation disclosures after a lawsuit and demand letters, keeping the September 23 shareholder vote on schedule.

Bio-Techne is a life-science tools company spanning Protein Sciences and Diagnostics and Spatial Biology, now under contract to be acquired by Merck KGaA for $73 per share in cash. The filing adds execution risk, not a new operating development. One shareholder lawsuit seeks to stop or delay the September 23 vote, while multiple demand letters challenge the proxy’s disclosures. The company calls the claims meritless but cannot estimate any potential loss or outcome. 〔0〕

The supplemental disclosures make the deal process more transparent without changing the deal economics. They reveal that Merck previously expressed interest at $92-$95 per share in 2023, but those discussions did not progress into a transaction. That history may intensify shareholder scrutiny, but it is too old to represent a live competing offer or a changed bid.

Filing disclosureFigure / comparison
Merck merger consideration$73 per share
2023 verbal Merck interest$92-$95 per share
Goldman Sachs present-value range$58-$72 per share
Goldman Sachs future-value present range$45-$74 per share
Goldman Sachs EBITDA reference range$49-$67 per share
LTM Adjusted EBITDA (Core)Approximately $421 million

The banker materials are mixed rather than decisively adverse to the transaction. The newly restated valuation analyses bracket the $73 offer unevenly: one range reaches $74, another stops at $72, and the EBITDA-based range tops out at $67. The disclosures therefore give shareholders more valuation context, but they do not establish that the agreed price falls outside Goldman Sachs’ broader analytical ranges.

The practical near-term issue is closing certainty. Bio-Techne is supplementing the proxy specifically to avoid the risk that the litigation could delay or adversely affect the merger, while leaving the September 23 meeting in place. 〔1〕

Bottom line: This is a process complication, not a revised merger proposal or a change in Bio-Techne’s business outlook. The added disclosures improve transparency, but the lawsuit and demands modestly increase uncertainty around the shareholder vote and closing timeline.

What to watch next

Shareholder vote on the Merck merger, September 23

Original filing on SEC EDGAR

More BIO-TECHNE Corp news

Bio-Techne amends Merck merger proxy as shareholder litigation targets vote | TECH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.